Leonard S. Schleifer

President and CEO at REGENERON PHARMACEUTICALS

Board

Since 1988

Age

71 years

Education

Earned an M.D. and a Ph.D. in Pharmacology from the University of Virginia.

Tenure

Founded REGN in 1988 and has served as its President and CEO since inception, also holding the roles of Chair of the Board from 1990 to 1994 and Co-Chair since June 2023.

Also at REGENERON PHARMACEUTICALS

Christopher Fenimore

Senior Vice President, Finance and CFO

DPVP

Daniel P. Van Plew

Executive Vice President and General Manager, Industrial Operations and Product Supply

Jason Pitofsky

Vice President, Controller

About

Leonard S. Schleifer has built a distinguished career in the biopharmaceutical industry by uniquely blending his expertise in medicine and research with innovative business leadership. His background in neurology and pharmacology has provided him with a solid foundation to drive complex research and strategic initiatives, positioning him as a key figure in groundbreaking drug development.

After founding REGN in 1988, he played an instrumental role in transforming the company into a leader in the field, overseeing the development of numerous innovative therapies and pioneering technologies. His leadership journey includes significant board-level responsibilities that have further underscored his commitment to excellence and continuous innovation in the biotechnology sector.

In addition to his professional achievements, his deep understanding of both the scientific and business aspects of the industry has been widely recognized, contributing to his reputation as an influential and visionary leader. His work continues to drive the company's success in an increasingly competitive market, reflecting his enduring impact on the biopharmaceutical landscape.

$REGN Performance Under Leonard S. Schleifer

Past Roles

Organization	Role	Date Range	Details
Regeneron Pharmaceuticals, Inc.	Chair of the Board	1990 - 1994	Served as Chair prior to his current executive roles

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,875,415	Annual	Fixed base salary component
All Other Compensation	$2,032,977	Annual	Includes: Life Insurance Premiums ($20,724 ), Disability Insurance Premiums ($8,465 ), Medical Malpractice Insurance Premiums ($28,822 ), 401(k) Matching ($15,000 ), Tax and Financial Planning Advisory Services ($11,200 ), Hart-Scott-Rodino Filing Fees ($400,000 ), Tax Reimbursement ($417,160 ), Personal Use of Company-Provided Aircraft ($250,000 ), Security Services ($881,606 )

Performance Compensation

Data from FY 2023

Cash-Based Performance Incentive

Metric Name	Value
Base Salary	$1,875,415
Cash Incentive Target	120% of Base Salary
Corporate Performance Multiplier	1.9
Total Cash Incentive Payout	$4,275,946
Vesting Schedule	Not Applicable (cash-based)
Evaluation Period	2023

Calculation Detail:

Base Salary × Cash Incentive Target × Corporate Performance Multiplier = Total Cash Incentive Payout. For example, $1,875,415 × 1.20 × 1.9 = $4,275,946.

Additional Information:

No individual performance multiplier was applied.
The 2023 annual cash incentive pool was adjusted based on the company’s performance against predefined R&D-related goals.